Net sales and order intake saw strong double-digit growth in Q2 2026, driven by the Medical Device Industry segment and robust performance in EMEA and APAC. EBITDA and net income improved significantly, supported by major new orders and operational efficiencies.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.